# Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)

Study · id `cardio:ct-nct02452736` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02452736](<https://clinicaltrials.gov/study/NCT02452736>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02452736

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

## Technical summary

Registry record NCT02452736. Allocation not applicable; no masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2015-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 205 participants (enrolled count; ClinicalTrials.gov record NCT02452736, source copy `cardio:ctgov-nct02452736-2016-04-07`, retrieved 2026-10-26)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02452736, source copy `cardio:ctgov-nct02452736-2016-04-07`, retrieved 2026-10-26)
- Primary completion: 2015-08 (actual) (ClinicalTrials.gov record NCT02452736, source copy `cardio:ctgov-nct02452736-2016-04-07`, retrieved 2026-10-26)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02452736, source copy `cardio:ctgov-nct02452736-2016-04-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02452736, source copy `cardio:ctgov-nct02452736-2016-04-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02452736-2016-04-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
- Condition: Ischemic Heart Disease
- Condition: Cardiovascular Diseases
- Condition: Arteriosclerosis
- Condition: Coronary Artery Disease
- Intervention (Device): Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Lead sponsor: Medtronic Vascular
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Medtronic Vascular (`cardio:org-medtronic-vascular`)

## Provenance

Content hash: 3e4d5f9e679909cc982f940d9b4ecf91b3e79dffb64f766da8daa5232177f858
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
